ArticleThe Lancet. Haematology2019

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Matthew S Davids et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.